WO2018182562A1 - Méthode de traitement d'affections cutanées des paupières - Google Patents

Méthode de traitement d'affections cutanées des paupières Download PDF

Info

Publication number
WO2018182562A1
WO2018182562A1 PCT/US2017/024201 US2017024201W WO2018182562A1 WO 2018182562 A1 WO2018182562 A1 WO 2018182562A1 US 2017024201 W US2017024201 W US 2017024201W WO 2018182562 A1 WO2018182562 A1 WO 2018182562A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
patient
treatment
eye lids
tenting
Prior art date
Application number
PCT/US2017/024201
Other languages
English (en)
Inventor
Vivi Robyn STAFFORD
Original Assignee
Stafford Vivi Robyn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stafford Vivi Robyn filed Critical Stafford Vivi Robyn
Priority to PCT/US2017/024201 priority Critical patent/WO2018182562A1/fr
Priority to MX2019011603A priority patent/MX2019011603A/es
Priority to CA3056919A priority patent/CA3056919A1/fr
Priority to EP17902778.4A priority patent/EP3600233A4/fr
Priority to CN201780090412.0A priority patent/CN110582264B/zh
Publication of WO2018182562A1 publication Critical patent/WO2018182562A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/882—Mixing prior to application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Definitions

  • This invention relates to a method of the treatment eye lids with nonsurgical blepharoplasty by injection to reverse skin tenting and upper eyelid overhang and lower lid laxity.
  • the present invention is directed to a method for the non-surgical reduction of localized loose skin in the upper and lower lids that is associated with the normal aging loss of the integrity of the dermis that supports the epidermis.
  • the upper lid tenting and overhang and lower lid tenting, overhang and laxity can give the appearance of one looking tired when not.
  • a treatment for skin tenting, lid laxity, sag and overhang in the upper and lower lids of the eyes with an aqueous solution of citric acid with a viscosity consistent with water at 20 to 25°C.
  • the Invention provides a method for improvement of the tired look of human skin of the eye lids comprising administering citric acid or a salt thereof to a patient in need thereof, wherein the administering is a subcutaneous injection.
  • the method tightens subcutaneous fat via strengthening of wall proteins located in the hypodermis of the skin of the upper and lower eye lids to thereby enhance facial appearance.
  • the injection is, for example, in the form of one or more large blebs or small boluses.
  • the method may also include an additional step of measuring one or more improvements in the appearance of the skin with a measuring device.
  • the citric acid or salt thereof When the citric acid or salt thereof is placed in the superficial plane or deep plains of subdermal fat, it causes skin tightening by connective tissue contractions, increase support of the subcutaneous tissue, and tensile strength to protein strands below the dermis.
  • the citric acid or salt thereof may be either natural or synthetic.
  • the compositions, treatment schedules and methods of using said compositions discovered by the inventor effectively remove the effect of tenting or impending tenting of the upper and lower lids.
  • tenting and impending tenting and tented skin ptosis of the upper and lower lids of the eyes are a well-known beauty problems; problems that can progress to visual impairment if treatment to reverse the presentation of the tented and hanging skin is delayed.
  • the effect of tightening tented and hanging skin with subcutaneous injections repositions fat and re- compartmentalizes fatty tissue in its more anatomically correct position.
  • Citrate constituted with isotonic water and dextrose can stimulate elastin tensile strength below the dermis and above and below the muscle to tighten skin, decrease the appearance of aging, and contour deficiencies, fine lines and wrinkles. Citrate is found in the serum of individuals, but also can be manufactured and processed.
  • composition of the instant application is based on 100 volume percent calculations.
  • the composition of the instant application is comprised of: 10 volume percent: 3.2 % sodium citrate buffer.
  • approximately .109 ml of sodium citrate buffer is used.
  • Citric acid having the formula,
  • the 3.2% sodium citrate buffer or citric acid is combined together with
  • the invention also encompasses a kit.
  • the kit includes the following items: 1). sodium citrate powder, or a solution thereof, pre-loaded into a 20 cc intravenous vial for dispensing, 2). an 8 to 10 cc syringe of a liquid volume comprising isotonic water, sodium chloride, glycerol and trace electrolytes; and an injector device to reconstitute the dry elements.
  • the injector mixes the ingredients back and forth between two 10 cc syringes until the formula is reconstituted to a dose of 10ml prior to administration.
  • the mixture should have a neutral pH prior to injection.
  • the prepared solution should exhibit the viscosity of water at 20 to 25°C at the time of injection.
  • composition of the instant application for the subcutaneous reversal of skin tenting, sag, lag of the upper and/or lower lid should be administered only by competent plastic surgeons, dermatologists or other medical doctors and their eligible licensed staff. Injections into the sub-dermal fat tissue in patients having skin tenting, sag or lag of the eye lids will tighten and thicken the subdermal fat bands and the hypodermis thereby reducing the appearance of fine lines, wrinkles, and pores of the eye lids.
  • Formulations suitable for administration conveniently comprise sterile aqueous solutions of the active ingredient(s). Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
  • Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
  • the formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.
  • An initial treatment period involves up to 2 to 3 treatments involving an initial treatment with usually two subsequent follow-up treatments, i.e. a follow-up treatment and a follow-up to the follow-up treatment.
  • a follow-up treatment When the appearance of the correction of the subcutaneous wall protein deficit of the upper and lower lids is observed, treatment is usually halted.
  • the consultant discusses the intended goals with the patient and then determines if the patient is a candidate for the follow-up to the follow-up treatment. The provider determines the appropriate number of milliliters of citric acid solution to be injected into the defective spaces of the subdermal fat planes; on average a range of 2 mis to 12 mis of citric acid solution is employed.
  • a hypodermic need is used to inject the citric acid with sterile water as an aqueous mixture in a micro droplet and microfluidic pattern into the defective space in the orbital lids targeting the preaponeurotic fat pads, medial fat pads, temporal fat pads, medial fat pads as well as the fatty cell layers.
  • the solution immediately reabsorbs into subdermal planes. Residual swelling will be appreciated for 24 hours followed by reabsorption of the solution.
  • the initial, local inflammatory response heals at a varying rate depending on the individual patient with the majority of patients healing completely within two weeks or less. Results from the treatment can be appreciated in 4 to 6 weeks with maximum results in 12 months and beyond. Blood test can be used to monitor the dermal response to the treatment. Before and after photography is used to consult with the recipient in one month, three months, 12 months as recommended visits and a 24-month visit with photography is optional.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

L'invention concerne une méthode destinée au resserrement sur l'hypoderme de cloisons de graisse et de réduction du plissage de la peau, du retard de la peau et du surplomb de la peau sur les paupières supérieures et inférieures.
PCT/US2017/024201 2017-03-26 2017-03-26 Méthode de traitement d'affections cutanées des paupières WO2018182562A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/US2017/024201 WO2018182562A1 (fr) 2017-03-26 2017-03-26 Méthode de traitement d'affections cutanées des paupières
MX2019011603A MX2019011603A (es) 2017-03-26 2017-03-26 Metodo de tratamiento de las condiciones de la piel de los parpados.
CA3056919A CA3056919A1 (fr) 2017-03-26 2017-03-26 Methode de traitement d'affections cutanees des paupieres
EP17902778.4A EP3600233A4 (fr) 2017-03-26 2017-03-26 Méthode de traitement d'affections cutanées des paupières
CN201780090412.0A CN110582264B (zh) 2017-03-26 2017-03-26 眼睑皮肤状况的处理方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/024201 WO2018182562A1 (fr) 2017-03-26 2017-03-26 Méthode de traitement d'affections cutanées des paupières

Publications (1)

Publication Number Publication Date
WO2018182562A1 true WO2018182562A1 (fr) 2018-10-04

Family

ID=63678310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/024201 WO2018182562A1 (fr) 2017-03-26 2017-03-26 Méthode de traitement d'affections cutanées des paupières

Country Status (5)

Country Link
EP (1) EP3600233A4 (fr)
CN (1) CN110582264B (fr)
CA (1) CA3056919A1 (fr)
MX (1) MX2019011603A (fr)
WO (1) WO2018182562A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136393A1 (fr) * 2018-01-05 2019-07-11 Stafford Vivi Robyn Procédé de resserrage non chirurgical de la peau par injection d'acide citrique sous-cutanée à l'exclusion de l'orbite

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB815517A (en) * 1955-06-20 1959-06-24 Upjohn Co Dihydro novobiocin, its salts and other derivatives and pharmaceutical compositions containing same
CA2153553A1 (fr) * 1994-07-13 1996-01-14 Hidekazu Suzuki Emulsion stable de lipides
CA2567803A1 (fr) * 2004-05-28 2005-12-15 Schering Corporation Suspension pharmaceutique injectable comprenant du posaconazole
US20120121585A1 (en) * 2010-11-15 2012-05-17 Novartis Ag SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
RU2512801C1 (ru) * 2012-10-08 2014-04-10 Ирина Юрьевна Юхман Лечебно-профилактический бальзам для глаз
US20140127227A1 (en) * 2011-10-28 2014-05-08 Byeong Seon Chang Protein formulations containing amino acids
US8846066B2 (en) * 2004-05-19 2014-09-30 The Regents Of The University Of California Methods and related compositions for reduction of fat and skin tightening
US20170087072A1 (en) * 2015-09-29 2017-03-30 Vivi Robyn Stafford Sodium Citrate (Citric Acid) Injections, intramuscular, below the dermis and in the facial soft tissue to stimulate the new synthesis of collagen in the skin and hence causing skin tightening

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE88352T1 (de) * 1988-02-26 1993-05-15 Genentech Inc Humanes relaxinpraeparat.
CA2552442A1 (fr) * 2002-12-31 2004-06-30 Avon Products, Inc. Compositions et procede d'administration pour le traitement de rides, fins sillons et de l'hyperhidrose
JP2004292400A (ja) * 2003-03-28 2004-10-21 Ichimaru Pharcos Co Ltd メイラード反応阻害剤及び化粧料組成物又は食品
EP1725245B1 (fr) * 2004-02-20 2012-01-25 Human Matrix Sciences, LLC Compositions pour elastogenese et traitement des tissus conjonctifs
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20070298005A1 (en) * 2006-06-22 2007-12-27 Marie-Josee Thibault Injectable composition for treatment of skin defects or deformations
WO2013033365A2 (fr) * 2011-08-30 2013-03-07 Biorestorative Therapies, Inc. Compositions de cellules souches et procédés
CN105338988B (zh) * 2013-06-18 2019-05-14 山东省药学科学院 黄原胶在制备注射美容产品中的用途
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
US20180078621A1 (en) * 2016-09-22 2018-03-22 Kyoung Lack Lee Composition for hypotonic lipolysis and manufacturing method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB815517A (en) * 1955-06-20 1959-06-24 Upjohn Co Dihydro novobiocin, its salts and other derivatives and pharmaceutical compositions containing same
CA2153553A1 (fr) * 1994-07-13 1996-01-14 Hidekazu Suzuki Emulsion stable de lipides
US8846066B2 (en) * 2004-05-19 2014-09-30 The Regents Of The University Of California Methods and related compositions for reduction of fat and skin tightening
CA2567803A1 (fr) * 2004-05-28 2005-12-15 Schering Corporation Suspension pharmaceutique injectable comprenant du posaconazole
US20120121585A1 (en) * 2010-11-15 2012-05-17 Novartis Ag SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
US20140127227A1 (en) * 2011-10-28 2014-05-08 Byeong Seon Chang Protein formulations containing amino acids
RU2512801C1 (ru) * 2012-10-08 2014-04-10 Ирина Юрьевна Юхман Лечебно-профилактический бальзам для глаз
US20170087072A1 (en) * 2015-09-29 2017-03-30 Vivi Robyn Stafford Sodium Citrate (Citric Acid) Injections, intramuscular, below the dermis and in the facial soft tissue to stimulate the new synthesis of collagen in the skin and hence causing skin tightening

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN, EF ET AL.: "Citric Acid Increases Viable Epidermal Thickness and Glycosaminoglycan Content of Sundamaged Skin", DERMATOLOGIC SURGERY, vol. 23, August 1997 (1997-08-01), pages 689 - 694, XP055641872 *
LAURSEN, T ET AL.: "Pain Perception after Subcutaneous Injections of Media Containing Different Buffers", BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY, 2006, XP055118277 *
See also references of EP3600233A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136393A1 (fr) * 2018-01-05 2019-07-11 Stafford Vivi Robyn Procédé de resserrage non chirurgical de la peau par injection d'acide citrique sous-cutanée à l'exclusion de l'orbite

Also Published As

Publication number Publication date
EP3600233A1 (fr) 2020-02-05
CN110582264A (zh) 2019-12-17
CA3056919A1 (fr) 2018-10-04
MX2019011603A (es) 2021-08-16
EP3600233A4 (fr) 2020-10-21
CN110582264B (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
Cohen Understanding, avoiding, and managing dermal filler complications
Hwang Periorbital injectables: understanding and avoiding complications
RU2690845C2 (ru) Способ для стимулирования роста волос и предотвращения выпадения волос пациента, вещество для него и способ получения вещества
Tran et al. Vision loss and blindness following fillers
Obagi et al. Autologous fat augmentation of the face
Bravo et al. Dermal thickness increase and aesthetic improvement with hybrid product combining hyaluronic acid and calcium hydroxyapatite: a clinical and sonographic analysis
RU2530629C2 (ru) Вызываемая медикаментозными средствами липоатрофия для косметических целей
US9744110B2 (en) Method of treating conditions of the eyelid
de Menezes Penedo et al. Improvement of facial skin laxity by a combined technique with hyaluronic acid and calcium hydroxylapatite fillers: a clinical and ultrasonography analysis
EP3600233A1 (fr) Méthode de traitement d'affections cutanées des paupières
Haq et al. Multinational, multipatient study of calcium hydroxylapatite for treatment of the aging hand: European Cosmetic Physician Group on Hand Augmentation
JP2021506985A (ja) 瘢痕を最小化することにおける使用のための神経毒
Matthews-Brzozowska et al. Mesotherapy–a method of facial skin rejuvenation from an interdisciplinary perspective on improving facial aesthetics
Hotta Lip enhancement: physical assessment, injection techniques, and potential adverse events
Barnett et al. Silicone augmentation of the lip
WO2015111034A1 (fr) Appareil et procédés de traitement de la peau, d'application d'un médicament et de formulation d'une crème
RU2659959C1 (ru) Состав препарата для коррекции дефектов кожи
KR102629903B1 (ko) N-아세틸글루코사민 유도체를 유효성분으로 함유하는 주입용 필러 조성물
RU2723140C1 (ru) Способ безоперационной коррекции формы лица
US20200016056A1 (en) Method of subcutaneous aqueous citric acid injection non-surgical skin tightening excluding orbit
Yanes et al. Poly-L-Lactic Acid
Mariwalla et al. Forehead Reflation
RU2721460C1 (ru) Способ безоперационной коррекции формы лица
Baker The use of hyaluronidase in aesthetic medicine: a literature review
Vu et al. HYALURONIC ACID FILLER INJECTION FOR COSMETIC PURPOSE: SKIN NECROSIS COMPLICATION AND TREATMENT-CASES REPORTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17902778

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3056919

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017902778

Country of ref document: EP

Effective date: 20191028